Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient Data
Lorenzo Gasperoni, Tiziano Lupi, Luna Del Bono, Valentina Polo, Andrea Messori, Vera Damuzzo · 2026
Read Comparative Efficacy of First-Line Therapeutic Options for ES-SCLC: An Indirect Comparison Using IPDfromKM-Reconstructed Individual Patient Data by Lorenzo Gasperoni, Tiziano Lupi, Luna Del Bono, Valentina Polo, Andrea Messori, Vera Damuzzo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13297242.txt.
Description
Lorenzo Gasperoni and colleagues indirectly compare first-line immunotherapy options for extensive-stage small cell lung cancer in a 2026 analysis. No trial has yet pitted the new combinations against each other directly. Patient-level data were reconstructed from the published survival curves of six major trials.
Serplulimab plus chemotherapy came out ahead in the reconstructed comparison. It extended life by roughly four months over chemotherapy alone, and by about two months over rival immunotherapy combinations. Fewer than seven percent of patients with this disease survive five years, so small gains matter. The authors hope the result prompts true head-to-head trials and guideline discussion about why this drug may work better.
Catalog record
| CREATOR | Lorenzo Gasperoni, Tiziano Lupi, Luna Del Bono, Valentina Polo, Andrea Messori, Vera Damuzzo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |